See personalized New Product recommendations! Get personalized New Product recommendations! Register or Login for personalized New Product recommendations!
Holiday Notification: Cayman Chemical will be closed Monday, May 28, 2012, in observance of the Memorial Day holiday.
More…
Please feel free to continue placing orders via our website or via fax at 734-971-3640. You may send an email to customer service at custserv@caymanchem.com , or to technical support at techserv@caymanchem.com which we will respond to the next business day. Cayman will resume regular business hours and shipping schedules on Tuesday, May 29, 2012. Thank you for your patience and understanding.
Research Area · Hypertension
· See all 100+ product categories
| Item Number | Product | Sizes & Pricing | CAS | Purity | Image | Exclusive | Introduction Date | Mojo | Plain Text Name | Synonyms | Keywords | Interest |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10007975 |
(±)11,12- |
- | ≥99% deuterated forms (d1-d11) |
|
✓ | 2008-03-17 | 13.530276243094 | -11-12-dhet-d11 | (±)11,12-DiHETrE-d11 | epoxides epoxygenases DHT hydrolases (+/-)11,12-DiHETrEs deuterated epoxide hydrolase deuterated deuterium | 13.530276243094 | |
| 10006413 |
11(12)- |
- | ≥99% deuterated forms (d1-d11) |
|
✓ | 2008-03-25 | 32.847163904235 | 11-12-eet-d11 | 11(12)-EpETrE-d11 | epoxides epoxygenases 11,12-EETs cytochrome P450 (+/-)11,12-EpETrEs (+/-)11(12)-EpETrEs deuterated deuterium | 32.847163904235 | |
| 10004549 |
11β- |
- |
|
2005-10-05 | 8.811786372007 | 11-hydroxysteroid-dehydrogenase-type-2-polyclonal-antibody | Corticosteroid 11β-Dehydrogenase Isozyme 2; 11β-HSD2 | proteins diseases antibodies antisera antiserum WB western blots blotting ICC immunocytochemistry corticosteroids regulations sodium homeostasis pathophysiology hypertension converts converting cortisol inactive cortisone mutations genes encoding induction hypertension hypokalemia syndromes mineralcorticoid excess mRNA expressed placenta target tissues kidneys mouse murine tissue-specific developmentally regulated glucocorticoid-medicated maturation 11b-HSD 11beta-HSD 11.beta.-HSD 11b HSD 11b-hydroxysteroid 11beta-hydroxysteroid endocrinology immunoblotting | 8.811786372007 | |||
| 10008040 |
(±)14,15- |
- | ≥99% deuterated forms (d1-d11) |
|
✓ | 2008-03-18 | 29.655414364641 | -14-15-dhet-d11 | (±)14,15-DiHETrE-d11 | epoxides epoxygenases DHT hydrolases (+/-)14,15-DiHETrEs deuterated epoxide hydrolase deuterium | 29.655414364641 | |
| 10004946 |
14,15- |
519038-92-7 | ≥98% |
|
✓ | 2007-01-15 | 53.788250460405 | 14-15-ee-5-z-e | 14,15-Epoxyeicosa-5(Z)-enoic Acid | 14,15-EpETrE 14,15-EETs antagonists hypertension vasodilation vasodilator vasoconstriction vasoconstrictor EDHT endothelium-derived hyperpolarizing factor U46619 bovine arteries endocrinology EEZE | 53.788250460405 | |
| 10010486 |
14,15- |
519038-93-8 | ≥98% |
|
✓ | 2008-11-03 | 14.701847759361 | 14-15-ee-8-z-e | 14,15-Epoxyeicosa-8(Z)-enoic Acid | 14,15-EETs 14,15-EpETrEs vasodilation vascular disease hypertension EEZE | 14.701847759361 | |
| 10009286 |
14(15)- |
218461-97-3 | ≥95% |
|
2007-05-14 | 23.609134438305 | 14-15-eet-si | 14(15)-EET-sulfonimide; 14(15)-EpETrE-SI | arachidonic acid AA endothelium epoxytrienoic acid EETs EpETrEs cytochromes P450 acetylcholine bradykinin sulfonamide analog tyrosine phosphorylation mitogenesis renal epithelial cells hypertension EDHF | 23.609134438305 | ||
| 10010635 |
(±)16- |
128914-46-5 | ≥98% |
|
2008-06-09 | 30.316611418048 | -16-hete | CYP450 eicosanoid metabolism kidneys ATPase ion transport vasodilation renal hypertension | 30.316611418048 | |||
| 10004385 |
16(R)- |
183509-22-0 | ≥98% |
|
2008-07-28 | 1.431491712707 | 16-r-hete | CYP450 eicosanoid metabolism kidney ion transport vasodilation renal hypertension HETEs | 1.431491712707 | |||
| 13076 |
16(R)- |
- | ≥98% |
|
2008-10-10 | 26.308745067087 | 16-r-iloprost | prostacyclin platelet aggregation IP receptors EP vasodilation pulmonary hypertension stereoisomers inhibits inhibitors inhibition iloprosts PGI2 | 26.308745067087 | |||
| 10004384 |
16(S)- |
183509-23-1 | ≥98% |
|
2008-07-23 | 1.556077348066 | 16-s-hete | inhibitors inhibits inhibitions CYP450 eicosanoid metabolism kidneys ATPase ion transport renal hypertension HETEs 16SHETE 16S-HETE 16 S HETE | 1.556077348066 | |||
| 13077 |
16(S)- |
74843-14-4 | ≥98% |
|
2008-10-10 | 27.445856353591 | 16-s-iloprost | prostacyclin platelet aggregation IP receptors EP vasodilation pulmonary hypertension stereoisomers iloprosts inhibits inhibitors inhibition PGI2 | 27.445856353591 | |||
| 10011305 |
17(S)- |
183509-25-3 | ≥98% |
|
2008-08-25 | 13.771176006313 | 17-s-hete | CYP450 Eicosanoid metabolism kidney ATPase ion transport renal hypertension | 13.771176006313 | |||
| 10010638 |
(±)18- |
133268-58-3 | ≥97% |
|
2008-06-13 | 2.947248618784 | -18-hete | CYP450 eicosanoid metabolism kidney vasodilation CYP2E1 20-HETE 20HETE 18HETE renal hypertension | 2.947248618784 | |||
| 10007767 |
19(R)- |
115461-39-7 | ≥98% |
|
2008-05-27 | 9.135911602210 | 19-r-hete | hypertension arterioles CYP450 kidneys angiotensin II vasodilator vasoconstricition 20-HETE 19HETE 19-HETE renal 19 HETE | 9.135911602210 | |||
| 10007766 |
19(S)- |
115461-40-0 | ≥98% |
|
✓ | 2010-04-06 | 39.957384898710 | 19-s-hete | cytochromes P450 CYP450 metabolites arachidonic acids kidneys angiotensin II CYP2E1 vasodilators renal preglomerular vessels ATPase hypertension arterioles vasoconstriction Acids Hydroxyeicosatetraenoic Hydroxyeicosatetraenoic Acids HETE | 39.957384898710 | ||
| 10007912 |
20- |
79551-84-1 | >98% |
|
✓ | 2007-08-15 | 47.112430939226 | 20-carboxy-arachidonic-acid | 20-COOH-AA | 20-HETE metabolites PPAR.alpha. PPAR.gamma. vasorelaxation activators CYP4F3B hypertension cytochrome P450 CYP450 perioxisome proliferator activated receptor PPARs PPARalpha PPARgamma | 47.112430939226 | |
| 10008596 |
5(6)- |
- | ≥95% |
|
2006-10-20 | 9.080923441200 | 5-6-eet-ethanolamide | 5(6)-EpETrE Ethanolamide | epoxides epoxygenases 5,6-EETs cytochrome P450 (+/-)5(6)-EpETrEs (+/-)5,6-EpETrEs fatty acids esters ethanolamides metabolites AEA anandamides arachidonoyl neurotransmitters cannabinergic endocannabinoids CB1 CB2 receptors central peripheral FAAH hydrolases metabolism lipoxygenases inhibition (±)5(6)-Epoxy eicosatrienoyl 14,15-EET 14,15-EpETrE 14,15-EET-EA 14,15-EET-ethanolamide 14,15-epetre-ea 14,15-ethanolamide cannabinoids cbs synthetic | 9.080923441200 | ||
| 13260 |
6- |
67786-53-2 | >99% |
|
60.945441988950 | 6-keto-prostaglandin-e1 | 6-keto PGE1 | 6-keto-PGE1 metabolites prostaglandins | 60.945441988950 | |||
| 10007210 |
6- |
67786-53-2 | >99% |
|
2008-11-03 | 40.630294659300 | 6-keto-prostaglandin-e1-lipid-maps-ms-standard | 6-keto PGE1 | 6-keto-PGE1 metabolites prostaglandins GC LC MS mass spectrometry standards GC/MS LC/MS GC-MS LC-MS | 40.630294659300 | ||
| 10009998 |
(±)8,9- |
- | ≥99% deuterated forms (d1-d11) |
|
✓ | 2008-03-17 | 10.037569060774 | -8-9-dhet-d11 | (±)8,9-DiHETrE-d11 | epoxides epoxygenases DHT hydrolases (+/-)14,15-DiHETrEs deuterated epoxide hydrolase deuterated deuterium | 10.037569060774 | |
| 18112 |
8,9- |
- | ≥95% |
|
✓ | 2009-03-15 | 13.174889502762 | 8-9-ee-14-z-e | 8,9-Epoxyeicosa-14(Z)-enoic Acid | 14,15-EETs 14,15-EpETrEs vasodilation vascular disease hypertension EEZE | 13.174889502762 | |
| 10009532 |
8(9)- |
- | ≥99% deuterated forms (d1-d11) |
|
2008-03-25 | 11.298416206261 | 8-9-eet-d11 | 8(9)-EpETrE-d11 | epoxides epoxygenases cytochrome P450 (±)8,9-EpETrEs (+/-)8,9-EpETrEs fatty acids (+/-)8(9)EpETrEs 8(9)EETs eicosatrienoic 8,9-EETs deuterated racemic mixture | 11.298416206261 | ||
| 10008597 |
8(9)- |
- | ≥98% |
|
2007-07-05 | 17.391712707182 | 8-9-eet-ethanolamide | 8(9)-EpETrE Ethanolamide | AEA endocannabinoids arachidonoyl ethanolamide CYP450 cytochrome P450 metabolism ethanolamides hypertension cannabinoids cbs synthetic | 17.391712707182 | ||
| 589320 |
8- |
- |
|
2008-05-21 | 664.292999210734 | 8-hydroxy-2-deoxy-guanosine-eia-kit | 8-OH-dG ELISA Kit; DNA Damage EIA Kit | solid plates oxidative injury stress aging cancers diabetes hypertension hydroxyl radicals peroxynitrite plasmas cells lysates tissues urine creatinine LC-MS liquid DNA damage kits EIAs chormatography mass spectrometry kits enzyme immunoassays elisas 8-OH-2-d 8OH2d 8 oxo deoxyguanine deoxyguanosine hydroxy ohdg 2 EIA/ELISA assays 8-ohdg 8ohdg | 664.292999210734 | |||
| 589451 | AcSDKP EIA Kit | - |
|
102.523756906077 | acsdkp-eia-kit | N-Acetyl Ser-Asp-Lys-Pro EIA Kit; AcSDKP ELISA Kit | N-Acetyl-Seryl-Aspartyl-Lysyl-Proline serine aspartamine lysine measures kits eias enzyme immunoassays ELISAs growth regulatory hormones plasma urine spi-bio spibio A05881 atherosclerosis hypertension endocrinology assays | 102.523756906077 | ||||
| 13620 | AL 6598 Exclusive | 170291-06-2 | 97% |
|
✓ | 2010-09-16 | 98.823082872928 | al-6598 | intraocular pressures IOPs glaucoma PGD2 agonists DP receptors eyes hypertension F2 alpha Prostaglandin Prostaglandin F2 alpha F2alpha Prostaglandin Prostaglandin F2alpha 9alpha,11beta-PGF2 9alpha,11beta PGF2 Prostaglandin F2 Enzaprost F alpha, PGF2 PGF2 alpha PGF2alpha Dinoprost Estrofan PGF2 | 98.823082872928 | ||
| 10004377 |
Aldosterone EIA Kit - |
- | 2004-04-21 | 275.969804788213 | aldosterone-eia-kit-monoclonal | Aldosterone ELISA Kit - Monoclonal | solid plates 582041 steroids hormones mineralocorticoids salt reabsorption electrolytes renin-angiotensin system RAS enzyme immunoassays eias elisas measures kits hypertension endocrinology assays | 275.969804788213 | ||||
| 13648 | Alfuzosin (hydrochloride) | 81403-68-1 | ≥98% |
|
2010-07-19 | 0E-12 | alfuzosin-hydrochloride | Uroxatral; SL 77499-10 | α1-adrenergic receptors antagonists lower urinary tract symptoms benign prostatic hyperplasia BPH adrenoceptors α1A α1B α1D contractions smooth muscles antihypertensives vasodilators urinary flow 133880-44-1 Urion Alfoten SL 77-499-10 anti-hypertensives alpha 1 .alpha.1 Xatral Quinazolines | 0E-12 | ||
| 10010663 |
Amlodipine- |
- | ≥99% deuterated forms (d1-d4) |
|
2009-08-10 | 0E-12 | amlodipine-d4-besylate | deuterateds deuteriums standards GC/MS LC/MS GC-MS LC-MS mass spectrometry dihydropyridine pyridines calcium channel blocker angina pectoris hypertension 88150-42-9 | 0E-12 | |||
| 589301 | Angiotensin II EIA Kit | - |
|
172.169052688316 | angiotensin-ii-eia-kit | Angiotensin II ELISA Kit | hypertension angiotensin measures kits eias enzyme immunoassays ELISAs spi-bio spibio A05880 atherosclerosis endocrinology assays | 172.169052688316 | ||||
| 13523 |
Apelin- |
217082-58-1 | ≥95% |
|
2010-06-29 | 36.988508287293 | apelin-13 | ligands APJ receptors central nervous system cardiovascular functions fluid homeostasis neurosciences hypertension diabetes metabolic syndrome insulin HIV aids Peptide Factors Paracrine Paracrine Protein Factors Paracrine Peptide Factors Growth Factors | 36.988508287293 | |||
| 13524 |
Apelin- |
252642-12-9 | ≥95% | 2011-04-04 | 34.961381215469 | apelin-36 | agonists receptors APJ cardiovascular functions fluids homeostasis hypertension insulin sensitivity apelin-17 apelins 17 13 36 apelin-13 HIV infections peptides mature G protein-coupled GPCR c-protein coupled | 34.961381215469 | ||||
| 583951 | Arginine Vasopressin EIA Kit | - |
|
2007-07-19 | 134.353838577948 | arginine-vasopressin-eia-kit | Vasopressin EIA Kit; AVP ELISA Kit; Antidiuretic Hormone (ADH) EIA Kit; Argipressin EIA Kit | solid plates enzymes immunoassays measurements arg8 measures kits eias ELISAs AChE acetylcholinesterases plasmas serums argipressin antidiuretic hormones ADH amino acids peptides regulates regulation renal water excretion cardiovascular mammals epithelial cells urinary tracts urine blood stimulates stimulation constriction capillaries aterioles pressure depressions congestive hearts failures anxious-retarded argipressins APH antidiuretics endocrinology assays 10009345 | 134.353838577948 | |||
| 589401 | Atriopeptin (rat) EIA Kit | - |
|
21.162430939227 | atriopeptin-rat-eia-kit | Atriopeptin (rat) ELISA Kit | naturiuretic auriculin measures kits eias enzyme immunoassays ELISAs atherosclerosis pi-bio spibio A05103 hypertension endocrinology assays | 21.162430939227 | ||||
| 10007927 | AUDA Exclusive | 479413-70-2 | >98% |
|
✓ | 2006-04-28 | 24.837419889502 | auda | epoxides hydrolases hypertension dihydroxy-eicosatrienoic acids DHETs 11(12)-EETs 14(15)-EETs blood pressure soluble sEH inhibits inhibitors inhibition peroxisome proliferator-activated receptors PPARalpha PPAR.alpha. DiHETrEs EpETrEs endocrinology | 24.837419889502 | ||
| 10489 | Candesartan cilexetil | 145040-37-5 | ≥98% |
|
2011-04-08 | 57.833971761817 | candesartan-cilexetil | TCV-116 | angiotensin II receptors antagonists hypertension diabetes AT1 type 1 stress diastolic blood pressure anti-hypertensive antihypertensive | 57.833971761817 | ||
| 10005186 | CAY10441 Exclusive | 221529-58-4 | >98% |
|
✓ | 2004-09-16 | 95.979825046041 | cay10441 | RO1138452 | receptors antagonists IPs prostaglandins carbaprostacyclins inhibits inhibitors inhibition analgesics high-affinity ligands neuroblastoma cyclic AMP cAMP adenylate cyclase 4,5-dihydro-1H-imidazol-2-yl-4-4-isopropoxy benzyl phenylamine atherosclerosis | 95.979825046041 | |
| 10005913 | CAY10449 Exclusive | - | >98% |
|
✓ | 2004-10-26 | 64.277476979742 | cay10449 | receptors antagonists IPs prostaglandins carbaprostacyclins inhibits inhibitors inhibition analgesics high-affinity ligands neuroblastoma adenylate cyclase cyclic AMP cAMP iloprost athersclerosis CAY 10449 | 64.277476979742 | ||
| 10012447 | CG 4305 | - | ≥95% |
|
2010-05-12 | 49.515730071033 | cg-4305 | antithrombotic PGI2 epoprostenol prostacyclins platelets aggregation 89955-40-8 PGs prostaglandins I2 cartoid artery thrombosis inhibits inhibited inhibition inhibitory Epoprostenol Sodium(5Z,9alpha,11alpha,13E,15S)Isomer Epoprostenol Sodium Prostaglandin I(2) Prostaglandin I2 Prostacyclin Epoprostenol Epoprostanol Flolan PGI2 PGX | 49.515730071033 | |||
| 30001 | cGMP Alprostadil GMP API | 745-65-3 |
|
0E-12 | cgmp-alprostadil | Prostaglandin E1 | 0E-12 | |||||
| 30024 |
cGMP Alprostadil- |
93591-00-5 | 2009-06-26 | 0E-12 | cgmp-alprostadil-alfadex | Prostaglandin E1 with α-cyclodextrin | 0E-12 | |||||
| 30010 | cGMP Epoprostenol (sodium salt) GMP API | 61849-14-7 |
|
2008-04-28 | 0E-12 | cgmp-epoprostenol-sodium-salt | Prostaglandin I2 (sodium salt); Prostacyclin (sodium salt) | 0E-12 | ||||
| 589101 | CGRP (human) EIA Kit | - |
|
196.930524861878 | cgrp-human-eia-kit | Calcitonin Gene-Related Peptide (human) EIA Kit; CGRP (human) ELISA Kit | calcitonin peptides measures kits eias enzyme immunoassays ELISAs spi-bio neurochemistry neuroscience spibio A05481 endocrinology assays | 196.930524861878 | ||||
| 10007923 | CUDA Exclusive | 479413-68-8 | ≥98% |
|
✓ | 2006-04-28 | 22.581843922652 | cuda | epoxides hydrolases hypertension dihydroxy eicosatrienoic acids DiHETrEs DHETs 11(12)-EETs 14(15)-EETs EpETrEs blood pressure soluble sEH inhibits inhibitors inhibition peroxisome proliferator-activated receptors PPARalpha PPAR.alpha. activates activation endocrinology | 22.581843922652 | ||
| 10018 | DDMS | 206052-03-1 | >98% |
|
2005-02-22 | 9.518784530387 | ddms | Dibromo-dodecenyl-methylsulfimide | 20-HETEs inhibits inhibitors inhibition synthesis CYP450-4A2 renal hypotension vascular homeostasis circulation kidneys vasodilation vasodilators NONOates CYP4A2 donors cytochrome | 9.518784530387 | ||
| 10012582 | Diallyl Disulfide New | 2179-57-9 | ≥90% |
|
2012-03-12 | 25.438090853284 | diallyl-disulfide | Garlicin; DADS; NSC 29228 | disulphide dipropenyl H2S hydrogen sulfide cardiovascular diseases neuroscience vascular tone vasorelaxation neuroprotection cardiology hypertension signal transduction NSC29228 NSC-29228 garlic plants allicin | 25.438090853284 | ||
| 10006865 | Docosahexaenoic Acid methyl ester | 2566-90-7 | ≥98% |
|
2005-09-06 | 87.794162062614 | docosahexaenoic-acid-methyl-ester | Cervonic Acid methyl ester; DHA methyl ester | polyunsaturated fatty acids PUFAs omega-3 brain .omega.-3 w-3 esters diets dietary supplements hypertension neonatal photoreceptor degeneration retinitis pigmentosa depiration neural tissues retina | 87.794162062614 | ||
| 10008610 | Epoxy Fluor 7 Exclusive | 863223-43-2 | ≥98% |
|
✓ | 2006-08-30 | 15.257403314917 | epoxy-fluor-7 | epoxides hydrolases fluorescence enzymes activity inhibition screening hypertension inflammation sepsis EETs DHETs EpETrEs DiHETrEs fluorescent SEH soluble endocrinology | 15.257403314917 | ||
| 11578 | Eprosartan (mesylate) New | 144143-96-4 | ≥98% |
|
2012-05-16 | 90.719337016575 | eprosartan-mesylate | SKF 108566J | cardiovascular diseases hypertension angiotensin II rennin blood pressure ARB receptors blockers antagonists AT1 mesylate nervous system nerves vessels | 90.719337016575 | ||
| 10010559 |
HA- |
203911-27-7 | ≥98% |
|
2008-09-03 | 53.702559852670 | ha-1077-hydrochloride | Eril; Fasudil; AT-877 | protein kinase inhibitors inhibits inhibition ROCK-II ROCKII PRK2 MSK1 MAPKAP-K1b vasodilation hypertension diabetes renal nephropathy cancers 105628-07-7 AT877 AT 877 hydrochloride dihydrochloride monohydrochloride HCl HA1077 HA 1077 | 53.702559852670 | ||
| 10011038 | Hemopressin | - | 2009-08-13 | 29.761006314127 | hemopressin | peptides antagonist inhibitors inhibits inhibition hypertension binding asoactive vasoactive cannabinoids cbs synthetic | 29.761006314127 | |||||
| 10005518 | IP Receptor (human) Polyclonal Antibody | - | 2004-10-21 | 25.489591774094 | ip-receptor-human-polyclonal-antibody | Prostaglandin I2 Receptor; Prostacyclin Receptor; PGI2 Receptor | antibodies antisera antiserum western blots blotting wb prostacyclins rat PGI2 prostaglandins receptors immunoblotting atherosclerosis | 25.489591774094 | ||||
| 10010572 |
Lercanidipine- |
- | >99% deuterated product |
|
2008-04-14 | 0E-12 | lercanidipine-d3-hydrochloride | SPI blocker calcium dihydropyrine neurochemistry | 0E-12 | |||
| 16833 | Lisinopril | 76547-98-3 | ≥98% |
|
2009-03-09 | 2.875414364640 | lisinopril | MK 522; MK 521 | inhibitors inhibits inhibition angiotensin I II ACE endothelin 1 nitric oxide renin hypertension diabetes | 2.875414364640 | ||
| 700570 |
L- |
- |
|
✓ | 2011-05-31 | 249.451887176504 | l-theanine-fluorometric-assay-kit | 5-N-ethyl-Glutamine; Glutamic Acid γ-ethyl amide; γ-ethylamino-L-Glutamic Acid; γ-Glutamylethylamide | kits assays measures measurements glutamines amino acids aa Camellia sinensis C. sinensis green teas japonica sasanqua mushrooms Xerocomus badius X. badius water-solubles non-proteins plants leaves umami humans immune systems .gamma..delta. gammadelta γδ T cells T-cells infection-fighting infections antigens ethylamine renal metabolites brains .alpha.-waves alpha-waves α-waves alertness schizophrenia neuroprotective effects glutamates receptors N-methyl-D-aspartate NMDA calcium Ca Ca2+ intracellular animals anthracyclines hypertensives rats antihypertensives blood pressures dopamines norepinephrines serotonins | 249.451887176504 | ||
| 10010971 |
Luminex® 11- |
- |
|
2008-01-24 | 43.918881343360 | luminex-11-dehydro-thromboxane-b2-kit | Luminex® 11-dehydro TXB2 Kit | thromboxanes thromboxane A2 TXA2 metabolites urine in vivo measures kits luminex xMAP beads assays | 43.918881343360 | |||
| 11215 | Lupeol New | 545-47-1 | ≥98% |
|
2012-02-15 | 22.361170100521 | lupeol | NSC 90487; Monogynol B; Fagarasterol; β-Viscol; Lupenol; Clerodol | AC-1371 AC1371 AC 1371 132473-92-8 200123-55-3 fagarsterol dietary triterpenes anti-inflammatory anticarcinogenic antimutagenic antimaralia fruits vegetables medicinal plants antimalarial cells carcinoma cancers SMMC7721 SMMC-7721 SMMC 7721 HepG2 melanoma mel928 mel-928 mel 928 mel1241 mel-1241 mel 1241 blood pressure strokes hypertension rats genes cholesterol synthesis neutrophils monogynol B NSC-90487 NSC90487 beta-viscol b-viscol | 22.361170100521 | ||
| 10010412 |
MRE- |
475085-57-5 | ≥98% |
|
✓ | 2008-11-06 | 63.403342541436 | mre-269 | MRE269 prostaglandins PGI2 IP receptors inflammation NS-304 NS304 agonists vasodilator hypotensive vascular diseases atherosclerosis hypertension analogs potent selective PGs prodrugs | 63.403342541436 | ||
| 11106 | Nifedipine | 21829-25-4 | ≥98% |
|
2011-11-22 | 0.798342541436 | nifedipine | Nifediac™; BAY 1040; Procardia™; Adalat™; Nifedical™; Cordipin | dihydropyridine calcium channel blockers Ca2+ hypertension angina endothelia cardiology preterm labor Raynaud’s phenomenon pulmonary edema coronary vasodilator antioxidant gastric acids 11104-22-6 101539-70-2 101554-38-5 adalat nifediac cordipin procardia nifedical adalate adapine adapress alat alfadat alonix angipec anifed BAY-1040 BAY1040 BAY-a BAYa BAY-a 1040 bonacid calcigard calcibloc calciguard calcilat camont cardifen cardionorm chronadalate coral cordafen cordaflex cordilan corinfar corotrend corynphar depin dignokonstant dilafed dilcor duranifin ecodipin fedcor fenamon fedipin fenihidine glopir hadipine hexadilat introcar kordafen macorel megalat myogard nifedilat nifedirex nifelantern nifelat nifensar niphedipine nyefax orix oxcord pidilat procardia sepamit TN 873R TN-873R TN873R tensopin tibricol UV-ENP 349PINa vasdalat vasofed xinran zenusin | 0.798342541436 | ||
| 10010653 |
Nisoldipine- |
1219795-47-7 | ≥99% deuterated forms (d1-d4) |
|
2009-04-15 | 0E-12 | nisoldipine-d4 | 63675-72-9 86189-67-5 calcium channel dihydropyridine cardiac failure angina deuterateds deuteriums standards GC/MS LC/MS GC-MS LC-MS mass spectrometry | 0E-12 | |||
| 10010411 |
NS- |
475086-01-2 | ≥98% |
|
2008-04-09 | 39.075902394106 | ns-304 | ACT-293987; Selexipag | prostaglandins PGI2 IP receptors inflammation MRE-269 agonists vasodilator hypotensive vascular diseases atherosclerosis hypertension analogs potent selective PGs | 39.075902394106 | ||
| 10006803 |
O- |
317321-41-8 | >98% |
|
2005-09-12 | 11.877928176795 | o-1602 | abnormal cannabidiols CB1 CB2 receptors vasorelaxation neurochemistry neuroscience central cannabinoids peripheral selective antagonists nonendothelium-dependant vasodilation nitric oxides NOs inhibits inhibitors inhibition vasorelaxant cannabinoids cbs synthetic | 11.877928176795 | |||
| 10006804 |
O- |
35482-50-9 | >97% |
|
2005-09-12 | 26.649907918968 | o-1821 | abnormal cannabidiol central cannabinoids peripheral CB1 CB2 receptors vasorelaxation neurochemistry neuroscience antagonists synthetic regioisomer endothelium dependent vasodilation cannabinoids cbs synthetic | 26.649907918968 | |||
| 10004914 |
O- |
536697-79-7 | >98% |
|
2005-09-09 | 11.646172059984 | o-1918 | antagonists abnormal cannabinoids cannabidiols cannabidiol-mediated synthetic regioisomers CB1 CB2 responsiveness psychotropics activity induces endothelium-dependent vasodilations NO-independent nitric oxides mechanisms analogs endothelial receptors inhibits inhibition inhibitors vasorelexants in vitro blocks induced activations PI3-kinases Akt pathway umbilical vein cells neuroscience neurochemistry O1918 0-1918 cannabinoids cbs synthetic | 11.646172059984 | |||
| 11614 | Olmesartan Medoxomil New | 144689-63-4 | ≥98% |
|
2012-05-18 | 99.077747084100 | olmesartan-medoxomil | Olmetec; Benicar; CS 866 | prodrugs angiotensin II receptors antagonists blood pressure hypertension cardiovascular disease atherosclerosis CS866 CS 866 in vivo RNH-6270 RNH 6270 RNH6270 AT1 AT2 blood pressure cardiovascular parameters CS-866 | 99.077747084100 | ||
| 600240 | Orexin 1 Receptor STEP Reporter Assay Kit (Luminescence) Exclusive | - |
|
✓ | 2010-03-31 | 10.428937998772 | orexin-1-receptor-step-reporter-assay-kit-luminescence | OX1R | hypercretins 1 orexins 2 A orexin-2 systems regulates regulator sleep wake cycles feeding cardiovascular autonomic hypothalamic neuropeptides Orexins A Orexins B gut hormones secretions hypothalamus midbrains brainstems G protein-coupled receptors GPCRs orexin-1 OX1R orexin-2 OX2R orexin-A orexin-B sleep disorders narcolepsy humans animals rodents energy homeostasis pain stress antagonists drugs addictions withdrawals therapeutics obesity Surface transfection expression protocols solid phase transient transfection technology originus patents USPT US6897067 US6902933 US7056741 US 6897067 6902933 7056741 DNA deoxyribonucleases adherent cells receptor-mediated luminescent secretory alkaline phosphatases SEAP signal transduction cascades culture medium luminescence-based high throughput screening screens agonists | 10.428937998772 | ||
| 600250 | Orexin 2 Receptor STEP Reporter Assay Kit (Luminescence) Exclusive | - |
|
✓ | 2010-03-31 | 9.883163122942 | orexin-2-receptor-step-reporter-assay-kit-luminescence | OX2R | hypercretins 1 orexin 2 systems regulates regulator sleep wake cycles feeding cardiovascular autonomic hypothalamic neuropeptides Orexins A Orexins B gut hormones secretions hypothalamus midbrains brainstems G protein-coupled receptors GPCRs orexin-1 OX1R orexin-2 OX2R orexin-A orexin-B sleep disorders narcolepsy humans animals rodents energy homeostasis pain stress antagonists drugs addictions withdrawals therapeutics obesity Surface transfection and expression protocols solid phase transient transfection technology originus patents USPT US6897067 US6902933 US7056741 US 6897067 6902933 7056741 DNA deoxyribonucleases adherent cells receptor-mediated luminescent secretory alkaline phosphatases SEAP signal transduction cascades culture medium luminescence-based high throughput screening screens agonists | 9.883163122942 | ||
| 70515 | Ozagrel | 82571-53-7 | ≥98% |
|
3.360220994475 | ozagrel | OKY-046 | thromboxanes synthases inhibitors inhibits imidizoles TXAs antihypertensive inhibition atherosclerosis | 3.360220994475 | |||
| 10007852 | Pargyline (hydrochloride) | 306-07-0 | >98% |
|
2006-08-30 | 54.197941988949 | pargyline-hydrochloride | MAO inhibitors inhibits inhibition ROS-mediated Hypertension 3 blood pressures systolic brains monocytes hypertrophy reactive oxygen species endocrinology | 54.197941988949 | |||
| 10009567 | PCSK9 Western Ready Control | - | 2007-01-31 | 7.817861089187 | pcsk9-western-ready-control | Proprotein Convertase Subtilisin Kexin 9; NARC-1 | PSEC0052 subtilisin serine proteases LDLs low density lipoproteins cholesterol receptors golgi atherosclerosis | 7.817861089187 | ||||
| 10009134 | PHOME Exclusive | 1028430-42-3 | ≥98% |
|
✓ | 2007-01-16 | 20.341977900552 | phome | sEH epoxides hydrolase inhibitors inhibition inhibits substrates HTS fluorogenic high throughput screening fluorescent fluorescence hypertension endocrinology | 20.341977900552 | ||
| 10011724 |
Propenyl- |
- | ≥90% |
|
✓ | 2008-08-19 | 8.798936464088 | propenyl-l-nio-hydrochloride | ENIPO | nitric oxide synthase NOS iNOS selective inhibitors inhibits inhibition | 8.798936464088 | |
| 10007599 | Prorenin (human recombinant) | - | ≥99% by SDS-PAGE | 2005-10-19 | 104.304737569060 | prorenin-human-recombinant | enzymes aspartyl proteases angiotensins II glycoproteins angiotensinogen salt balance hypertension angiotensinogens kidney renal preprorenin endocrinology | 104.304737569060 | ||||
| 10010 | Prostaglandin A1 | 14152-28-4 | >98% |
|
146.280828729282 | prostaglandin-a1 | PGA1 | prostaglandins renal vasodilation pge1 dehydration semen antimitotic antiproliferative | 146.280828729282 | |||
| 10020 | Prostaglandin A1 ethyl ester | 93464-24-5 | >98% |
|
73.642265193370 | prostaglandin-a1-ethyl-ester | PGA1 ethyl ester | PGA1 renal vasodilation prostaglandins esters prodrugs lipid-soluble | 73.642265193370 | |||
| 9000184 | Prostaglandin A1 methyl ester Exclusive | 26771-94-8 | ≥98% |
|
✓ | 2010-11-08 | 19.534551104972 | prostaglandin-a1-methyl-ester | PGA1 methyl ester | hypertension cancers lipophilic analogs PGA1 prostaglandins | 19.534551104972 | |
| 12990 | Prostaglandin D3 Exclusive | 71902-47-1 | >98% |
|
✓ | 72.632799263352 | prostaglandin-d3 | PGD3 | PGD3 omega-3 w-3 .omega.-3 metabolites EPA eicoaspentaenoic acid prostaglandins | 72.632799263352 | ||
| 13010 | Prostaglandin E1 | 745-65-3 | >98% |
|
48.090448127685 | prostaglandin-e1 | Alprostadil; PGE1 | PGE1 vasodilation atherosclerosis erectile dysfunction prostaglandins pharma:1 | 48.090448127685 | |||
| 13010.1 | Prostaglandin E1 Analytical Reference Standard | 745-65-3 | >99% |
|
33.304401473296 | prostaglandin-e1-analytical-reference-standard | Alprostadil; PGE1 | PGE1 vasodilation USP erectile dysfunction prostaglandins | 33.304401473296 | |||
| 10006906 | Renin Fluorogenic Substrate | - | >95% | 2006-12-12 | 63.743351749539 | renin-fluorogenic-substrate | substrates aspartyl proteases angiotensinogens peptides peptide-EDANS non-fluorescent quenching molecules Dabcyl fluorescent excitation emission hypertension endocrinology | 63.743351749539 | ||||
| 10006217 | Renin (human recombinant) | - | >99% by SDS-PAGE | 2004-12-13 | 53.759364640884 | renin-human-recombinant | enzymes aspartyl proteases angiotensins II glycoproteins angiotensinogen salt balance hypertension angiotensinogens kidney renal preprorenin atherosclerosis endocrinology active | 53.759364640884 | ||||
| 10006270 | Renin Inhibitor Screening Assay Kit | - |
|
2005-05-04 | 55.100208717004 | renin-inhibitor-screening-assay-kit | Protease measurement assays aspartyl renal juxtaglomerular cells sodium depletion blood volume pressure .beta.-adrenergic stimulation angiotensinogens angiotensins I II converting ACE monomeric zinc metalloenzymes vascular endothelium messengers RAS vasoconstrictor peripheral hypertension receptors blockers fluorescence fluorescent fluorometric atherosclerosis endocrinology | 55.100208717004 | ||||
| 13082 | Resorcinolnaphthalein | 41307-63-5 | ≥98% |
|
2009-02-24 | 48.882817679557 | resorcinolnaphthalein | NSC 354317 | angiotensin converting enzyme 2 ACE2 hypertension blood pressure activators fibrosis | 48.882817679557 | ||
| 10010662 |
Rilmenidine- |
85047-14-9 | ≥99% deuterated product |
|
2009-04-17 | 0.795580110497 | rilmenidine-d4 | adrenergic agonist agents antihypertensive deuterateds deuteriums standards GC/MS LC/MS GC-MS LC-MS mass spectrometry | 0.795580110497 | |||
| 10008609 |
S- |
- | ≥98% |
|
✓ | 2007-05-01 | 15.429898710865 | s-nepc | Cytochrome P450 CYP450 subtrates glutathione s-transferase hydrolases procine liver carboxylesterase hydrolysis spectrophotometry (+)-NEPC (-)-NEPC hypertension sEH epoxides sEH inhibitor substrate GST endocrinology | 15.429898710865 | ||
| 600090 |
Soluble Epoxide Hydrolase Cell- |
- |
|
2009-05-14 | 12.481026045777 | soluble-epoxide-hydrolase-cell-based-assay-kit | sEH Cell-Based Assay Kit | kits assays measuring measurement mammalian epoxides α/β-hydrolases enzymes catalyzes hydrolysis exogenous endogenous vicinal diols homodimers C-terminal N-terminal domains vasodilatory vasodilation anti-inflammatory hypertension vascular inflammation inhibitors therapeutics fluorescence-based fluorescent whole cells Epoxy Fluor 7 6-methoxy-2-naphthaldehyde AUDA | 12.481026045777 | |||
| 10011669 | Soluble Epoxide Hydrolase (human recombinant) | - | ≥95% |
|
2008-07-02 | 10.534812154695 | soluble-epoxide-hydrolase-human-recombinant | CEH; Cytosolic Epoxide Hydrolase; sEH; Epoxide Hydrolase 2; EPHX2 | recombinant proteins mammalian hydrolases enzymes exogenous endogenous his-tags hexahistindes His-tagged anti-inflammatory inflammation sehs hydrolases hydrolysis active | 10.534812154695 | ||
| 10011671 | Soluble Epoxide Hydrolase Inhibitor Screening Assay Kit | - |
|
2009-02-24 | 8.720009208103 | soluble-epoxide-hydrolase-inhibitor-screening-assay-kit | sEH Inhibitor Screening Assay Kit | epoxides hydrolases sEHs inhibits inhibition assays kits fluorescence-based catalyzes hydrolysis exogenous endogenous vicinal diols substrates EETs epoxyeicosatrienoic acids vasodilatory vasodilation anti-inflammatory molecules therapy therapeutics hypertension vascular diseases PHOME (3-phenyl-oxiranyl)-acetic acid cyano-(6-methoxy-naphthalen-2-yl)-methyl ester 6-methoxy-2-naphthaldehyde excitation emission wavelengths a/b-hydrolases alpha/beta-hydrolases .alpha./.beta.-hydrolases enzymes homodimers C-terminal C-terminus animals models cyanohydrins cyanide ions | 8.720009208103 | |||
| 10011670 | Soluble Epoxide Hydrolase (mouse recombinant) Exclusive | - | ≥95% |
|
✓ | 2008-07-01 | 7.344784530387 | soluble-epoxide-hydrolase-mouse-recombinant | Cytosolic Epoxide Hydrolase; EPHX2; Epoxide Hydrolase 2; CEH; sEH | recombinant proteins mammalian hydrolases enzymes exogenous endogenous hexahistidine His-tag His-tagged N-terminal anti-inflammatory inflammation 10278 active | 7.344784530387 | |
| 10010146 | Soluble Epoxide Hydrolase Polyclonal Antibody | - |
|
2008-03-03 | 6.894585635359 | soluble-epoxide-hydrolase-polyclonal-antibody | Epoxide Hydrolase 2; EPHX2; sEH; Cytosolic Epoxide Hydrolase (CEH) | metabolism hypertension inflammation EpETrEs EETs DiHETrEs DHET inhibitors inhibit inhibitions epoxyeicosatrienoic acids eicosatrienoic WB western blots blotting immunoblotting | 6.894585635359 | |||
| 11615 | Telmisartan New | 144701-48-4 | ≥98% |
|
2012-05-09 | 89.077747084100 | telmisartan | Pritor; BIBR 277; Micardis | BIBR 277SE BIBR277 BIBR-277 receptors antagonists blood pressure hypertension PPAR PPARγ atherosclerosis cardiovascular disease angiotensin hormones hearts myocardial infarction hypertrophy renal glomerulosclerosis | 89.077747084100 | ||
| 11120 | TPPU Exclusive | 1222780-33-7 | ≥98% |
|
✓ | 2011-10-26 | 5.145469613259 | tppu | soluble epoxide hydrolase sEH inflammation hypertension cardiovascular disease neuroscience inhibitors inhibits inhibition pharmacokinetics | 5.145469613259 | ||
| 10162 | Treprostinil | 81846-19-7 | >98% |
|
2005-08-30 | 75.237668508287 | treprostinil | Remodulin® | primary pulmonary hypertension PPH arterial vascular resistance stable analogs prostacyclins increase plasma half-life vasodilatory inhibits inflammatory cytokines inhibition inhibitors GM-CF human alveolar macrophages NF-KB NF-.kappa. translocations nucleus NF-kappaB nfkb nf-kb NF-.kappa.B atherosclerosis Tyvasos Tyvaso® | 75.237668508287 | ||
| 700320 | Uric Acid Assay Kit | - |
|
2010-08-30 | 115.979321692528 | uric-acid-assay-kit | Urate Assay Kit | kits assays measures measurement acids human purines metabolisms urine serum renal excretion excreted allantoin enzymes urate oxidases uricase genes obesity alcohol consumption hyperuricemia gout kidney stones metabolic syndromes hypertension cardiovascular diseases exercise-induced acute failure hypouricemia | 115.979321692528 | |||
| 11791 | Vitamin D2 New | 50-14-6 | ≥98% |
|
2012-05-24 | 148.659649122807 | vitamin-d2 | Infron; Uvesterol D; Davitamon D; Fortodyl; Mulsiferol; Calciferol; NSC 62792; Ergocalciferol; Radiostol | buco-D condocaps condol crystallina D-arthin D-tracetten davitin De-rat concentrate decaps dee-osterol dee-ron dee-ronal deltalin deratol detalup diactol divit urto doral drisdol ercalciol geltabs hi-deratol ergorone ertron metadee mina D2 mykostin NSC62792 NSC-62792 oleovitamin D oleovitamin D2 osteil ostelin radsterin rodine C shock-ferol sterogyl vio D viosterol vitamin D2 vitavel-D 7489-18-1 8017-28-5 31316-19-5 bones cancers hypertension immunity yeast fungi invertebrates vitamins ergosterol ultraviolet radiation organisms 25-hydroxyvitamin 25-hydroxy vitamin 1,25-dihydroxyvitamin 1,25-dihyrdroxyvitamin | 148.659649122807 | ||
| 11792 | Vitamin D3 New | 67-97-0 | ≥98% |
|
2012-05-24 | 149.379884182525 | vitamin-d3 | Arachitol; Delsterol; Quintox; Granuvit D3; Lutavit D; NSC 375571; Ricketon; Cholecalciferol; Trivitan | calciol calcirol D3-vigantol decristol deparal devaron dry vitamin D3 100CWS/AM duphafral D3 1000 ekostop D3 FeraCol high-D 2X oleovit D3 oleovitamin D3 riken D3 oil 100 riken D3 oil 20 UVEDOSE Vi- De3 videkhol vigantoletten vigorsan vitinc dan-dee-3 8024-19-9 8050-67-7 bones hypertension cancers immunity dietary fish 7-dehydrocholesterol ultraviolet lights metabolized 25-hydroxyvitamin 25- hydroxy vitamins 1,25-dihydroxyvitamins 1,25-dihydroxy vitamins cytochrome P450 CYP450 isoforms livers retinoid X receptors genes expressions | 149.379884182525 |
Cayman Chemical Company · 1180 East Ellsworth Road · Ann Arbor, Michigan 48108 · USA
Toll Free: (800) 364-9897 (USA and Canada Only) · Fax: (734) 971-3640
Copyright 2012 Cayman Chemical Company
Quick Search